Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results
Date:2/8/2016

SAN DIEGO, Feb. 8, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2015 results after the Nasdaq market closes on Thursday,  February 11, 2016.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 11, 2016 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Participants can access the live conference call by dialing 866-952-7534 (US) or 785-424-1835 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-677-6124 (US) or 402-220-0664 (International) using the conference ID: NBIX. The call will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
2. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
3. Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
4. Neurocrine Biosciences to Present at Credit Suisses 24th Annual Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
6. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
7. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
8. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
9. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
10. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
11. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... , ... While coronavirus cases continue to increase across the country, blood drives ... closed. Because about 80% of blood donations are made at drives hosted by these ... drive hosts to ensure blood products are readily available for patients. , Those ...
(Date:8/31/2020)... ... , ... Continuing on its rapid national expansion - ... provider - is proud to announce it has opened doors in Phoenix, Arizona. ... throughout the area. , Germinator provides a 100% safe and non-toxic sanitizing and ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a ... successful completion of their 2020 System and Organizational Controls (SOC) 1® Type 2 ... and MARS-E compliance assessment. These achievements reflect their long-standing commitment to privacy, security, ...
Breaking Medicine Technology:
(Date:9/1/2020)... ... 2020 , ... KitoTech Medical, a Seattle-based medical device company, ... be used to accelerate the commercialization of its microMend® family of wound closure ... to expand its customer base of healthcare systems as well as independent hospitals ...
(Date:8/31/2020)... ... August 31, 2020 , ... The ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its international Light ...
(Date:8/31/2020)... AURORA, Colo. (PRWEB) , ... August 31, 2020 ... ... premier provider of innovative higher-learning opportunities through high-quality, career-relevant, and affordable online education ... Emergency Responder Psychology . , Among the first of its kind in ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has over 20 ... and other developmental disabilities, as well as supporting staff in caring for patients ... school consultation, and staff development. She joined the company in 2015 as Chief ...
(Date:8/28/2020)... ... August 28, 2020 , ... The 15 scholarships ... Lighthouse Health & Wellness mobile app and web-portal. NCPCV received a 2020 grant ... awards grants each year to organizations, such as Destination Imagination, which support and ...
Breaking Medicine News(10 mins):